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Abstract
Background: Artesunate+amodiaquine (AS+AQ) and artemether-lumefantrine (AL) are now the most frequently
recommended first line treatments for uncomplicated malaria in Africa. Artesunate+chlorproguanil-dapsone (AS+CD) was
a potential alternative for treatment of uncomplicated malaria. A comparison of the efficacy and safety of these three drug
combinations was necessary to make evidence based drug treatment policies.
Methods: Five hundred and thirty-four, glucose-6-phosphate dehydrogenase (G6PD) normal children were randomised in
blocks of 15 to the AS+AQ, AL or AS+CD groups. Administration of study drugs was supervised by project staff and the
children were followed up at r home on days 1,2,3,7,14 and 28 post treatment. Parasitological and clinical failures and
adverse events were compared between the study groups.
Main Findings: In a per-protocol analysis, the parasitological and clinical failure rate at day 28 post treatment (PCF28) was
lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8%
respectively, p=0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, p=0.005). In the intention to treat analysis, the
rate of early treatment failure was high in all three groups (AS+AQ 13.3%; AL 15.2%; and AS+CD 9.3%, p=0.2) primarily due
to vomiting. However, the PCF28 corrected for re-infection was lower, though not significantly, in the AS+AQ group
compared to the AL or the AS+CD groups (AS+AQ 18.3%; AL 24.2%; AS+CD 20.8%, p=0.4) The incidence of adverse events
was comparable between the groups.
Conclusions:AS+AQisan appropriate first line treatment for uncomplicated malariainGhana and possiblyinthe neighbouring
countries in West Africa. The effectiveness of AL in routine programme conditions needs to be studied further in West Africa.
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Introduction
There is now widespread acceptance that combination therapy
($2 antimalarial drugs with different modes of action) is a better
option than monotherapy for the treatment of uncomplicated
malaria and artemisinin based combination therapy (ACT) is
advocated as a way forward.[1] The WHO recommends
artesunate+amodiaquine (AS+AQ), artemether-lumefantrine (AL)
or artesunate+sulphadoxine-pyremethamine (AS+SP) as the first
line treatment for uncomplicated malaria in Africa.[2] By
November 2006, most malaria endemic countries in Africa (33/
42) had adopted ACT as the first line treatment for uncomplicated
malaria.[3] In 2002, Ghana adopted AS+AQ as first line
treatment based on the evidence of its efficacy and safety observed
elsewhere in Africa and on account of its potential for production
by local manufacturers.[4] Randomised controlled efficacy trials in
Zanzibar,[5] Uganda[6] and Angola[7] had shown that polymer-
ase chain reaction ( PCR) corrected adequate clinical response
rates at day 28 post treatment (ACPR28) were very high for both
AS+AQ (94–100%) and AL (97–100%). In 2003, a four arm
comparative efficacy trial in Ghana showed that the ACPR28 was
100% (n=51) for AL and 97.5% (n=54) for AS+AQ.[8]
However, a randomised trial of the effectiveness of AS+AQ and
AL in Tanzania showed that the parasitological failure at day 28
was 2.6 fold (95% CI 1.9–3.4) higher in the AS+AQ group (40%)
compared to the AL group (21%).[9] Artesunate+chlorproguanil-
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because chlorproguanil-dapsone has been shown to be efficacious
in areas with high SP and chloroquine resistance.[10] Clinical
trials of AS+CD have been carried out in several countries in
Africa (www.ispub.com/ostia/index.php?xmlFilePath=journals/
ijid/vol4n2/cda.xml) but the development of AS+CD was
abandoned recently due to safety concerns in glucose-6-phosphate
dehydrogenase (G6PD) deficient subjects. There has been no
comparative studies of the efficacy and safety of AS+CD versus
AS+AQ or AL. Even though most countries in Africa have
adopted ACT as first line treatment, antimalarial monotherapy is
still common and this can undermine the efficacy of ACT.
Furthermore high levels of resistance to AQ already exists in many
parts of Africa.[9] Thus, it is important to evaluate the efficacy of
ACTs particularly that of AS+AQ periodically. In this paper, we
report the results of a randomised trial that compared the efficacy
and safety of AS+AQ, AL and AS+CD in children in Ghana.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see checklist S1 and
Protocol S1.
Participants
The study was conducted in Kintampo district hospital,
Brong-Ahafo region, Ghana. Malaria transmission in this forest
region of Ghana is perennial but peaks in July–August and the
entomological inoculation rate is high, about 270 infective bites
per person per year. Although the study area has high
transmission, malaria is common in older children and therefore
the study included children up to 10 years of age. From June
2005 to May 2006, 1718 children aged 6 months to 10 years
who attended the study hospital’s outpatient department with a
history of fever or an axillary temperature $37.5uC were
examined for malaria parasitaemia and screened for their
eligibility for enrolment in this study after written, informed
consent had been obtained from their caretakers (Figure 1).
Children who had a body weight #5 kg, Hb ,7 g/dL, malaria
parasitaemia ,2000 or .200000 parasites/mL, danger signs
(unable to drink, history of repeated vomiting, convulsions or
other signs of severe malaria, or any other concomitant febrile
disease were excluded from the study but offered standard care
according to Ministry of Health guidelines. Children were
screened for glucose-6-phosphate dehydrogenase (G6PD) defi-
ciency before randomisation (the G6PD test took about 1hour). A
total of 630 children were eligible; 534 were G6PD normal and
96 were G6PD deficient. The G6PD normal children were
randomly assigned to the AL, AS+AQ, or AS+CD groups. The
G6PD deficient children were randomised to the AS+AQ or AL
group only because the Ghana Ministry of Health Ethical
Committee expressed concern about the possibility of haemolysis
associated with chlorproguanil-dapsone treatment in G6PD
deficient children.
Figure 1. Enrolment and Follow up profile.
doi:10.1371/journal.pone.0002530.g001
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Administration of the first dose of study drugs was supervised by
a study nurse and the administration of subsequent doses was
supervised by study field workers. All children were given iron
along with antimalarials according to national treatment guide-
lines. Caretakers of children in the AL group were told about the
need to give a fatty meal along with the drug. Children were
actively followed up at their homes by 10 field workers on days 1,
2, 3, 7, 14 and 28 post treatment to solicit adverse events. Finger
prick blood samples for parasitological observations were obtained
on days 3, 7, 14, 28, for haematological measurements on days 1,
2, 3, 7, 28 and for biochemical assessments on days 2, 7, 28 (0.7ml
of capillary blood) after the start of treatment. Blood samples were
collected from children who attended the study clinic for suspected
malaria on any other day outside the scheduled days of follow up.
There were 77 unscheduled visits and those who had a positive
blood slide on these unscheduled visits (n=15) were treated with
quinine and classified as treatment failures.
Randomisation
Randomisation was done using Microsoft Excel 2003

randomisation generator. G6PD normal children were rando-
mised in blocks of 15 to the AL, AS-AQ, or AS+CD group. G6PD
deficient children were randomised in blocks of 10 to AL or AS-
AQ group. Co-blistered packs of artesunate and amodiaquine
(Arsucam,H Sanofi-Aventis), artemether-lumefantrine (Coartem,

Novartis) and chlorproguanil-dapsone (Lapdap,
TM GlaxoSmithK-
line) were obtained from the respective local suppliers.
Statistical Methods
Data were double-entered, and validated using Visual Foxpro

6.0.and the analysis was done using Stata
TM 9.1. Per protocol
analysis included patients who were properly randomised, had
received the study drugs according to the protocol, and for whom
data were available on the primary end point (ACPR28). Intention
to treat (ITT) analysis involved all randomised patients irrespective
of how many doses of the study drugs had been given but excluded
all major day 0 protocol violations. All statistical tests were two-
sided and an a-level ,0.05 was considered a statistically significant
result. For comparisons of continuous variables between groups,
the t-test was used and for comparisons between more than two
groups, one-way analysis of variance was used after assuring
normality and homogeneity of variances assumptions were
satisfied. For comparison of categorical variables, the chi-square
test was used with the exact extension invoked when there were
small numbers in the cells. A survival analysis using the life table
method was done on the cumulative proportion of children having
treatment failure at different time points during the post treatment
period in each of the arms of the study. The end points were any of
the following: failure to take the drug on any of the first three days,
parasitaemia on day 2 greater than that on day 0, presence of
parasitaemia on day 7, diagnosis of severe malaria at any point
after day 0, recurrent parasitaemia after day 7 up to day 28. The
likelihood-ratio test statistic of homogeneity and the logrank tests
of homogeneity of arm were also carried out.
Sample size
The primary endpoint was PCR corrected ACPR by day 28. A
sample size of 510 children was chosen on the basis of the
following assumptions: (1) the efficacy of AL would be 95%; (2) the
study would have 80% power at 95% significance level to detect a
10% difference in efficacy as measured by the parasitological
failure at day 28 post-treatment in the AS+AQ, and AS+CD
groups compared with the AL group; (3) loss to follow up by day
28 post treatment would be ,5%.
Laboratory procedures
At least 200 oil immersion fields of thick blood films stained with
Giemsa stain were examined for malaria parasites before a blood
film was considered negative. The parasite density per micro-litre
was estimated by multiplying the number of parasites per 200
leukocytes by a factor of 40, assuming a white blood cell count of
8,000/ml. Each blood slide was read by two microscopists. If the
difference in the parasite density estimated by the two microscopists
was ,50%, the mean of the two readings was defined as the true
parasite density. If the disagreement between the two readings was
$50%, a third microscopist examined the slide and the mean of the
two closest readings was deemed to be the true parasite density. To
distinguish between recrudescent and new infections, parasites
identified on Days 14 and 28 were compared to those identified at
enrolment using PCR amplification of msp2 P. falciparum genes. Full
blood count and biochemical tests were done by calibrated
automated ABX MICROS 60 (Horiba ABX, France) and Selectra
E Clinical Chemistry Analyzer (Vital Scientific N.V, Netherlands)
respectively. Quantitative G6PD phenotype analysis was conducted
using Randox method with Humalyser Junior (Human, Germany).
Plasma ALT, AST, Total Bilirubin, Creatinine and Urea were
measured on the Selectra E Clinical Chemistry analyzer (Vital
Scientific, The Netherlands) using reagents from Elitech Diagnostics
(Sees, France). ALT and AST were measured using the kinetic, UV,
IFCC method without pyridoxal phosphate, total bilirubin with the
modified Evelyn-Malloy method, creatinine with the kinetic Jaffe
method and urea with the kinetic urease method. Glucose-6-
phosphate dehydrogenase (G6PD) activity was measured using a
quantitative UV G6PD kit from Randox (Antrium, UK). The
enzyme activity was determined by the measurement of the rate of
absorbance change at 340 nm due to the reduction of NADP
+.
Ethics
The study protocol was approved by the ethics committees of the
Kintmapo Health Research Centre, Ghana Ministry of Health and
the London School of Hygiene & Tropical Medicine. The study is
registered at the United States National Institute of Health clinical
trials register; the registration number is NCT00119145 and the
URL:https://clinicaltrials.gov/ct2/show/NCT00119145/
Results
G6PD normal children
There were no statistically significant differences in the
demographic or baseline haematological characteristics between
the three treatment groups at enrolment (Table 1).
In the per-protocol (PP) analyses there were no statistically
significant differences in the rates of early treatment, late
treatment, parasitological or clinical failures at day 14 between
the three groups (Table 2). Survival analysis showed that there was
no statistically significant differences in treatment failure at
different time points during the 28 day post treatment period
between the three groups (Figure 2). However, the parasitological
and clinical failure rate at day 28 (PCF28) uncorrected for re-
infections was significantly lower in the AS+AQ group (14.6%)
compared to the AL (27.6%) or AS+CD (28.1%) groups (Table 2).
The PCF28 corrected for re-infection was also lower in the
AS+AQ group (6.6%) than in the AL (13.8%) or AS+CD (13.8%)
groups but this difference was not statistically significant. PCF28
uncorrected for re-infection was nearly 50% less in the AS+AQ
group compared to AL and AS+CD groups (Table 3). PCF28
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group compared to AS+CD group (RR 0.43; 95% CI 0.20, 0.89).
There was no significant difference in the PCF28 between AL and
AS+CD groups (Table 3).
In the intention to treat analyses, the rate of early treatment
failure was high in all three groups (13.3% in AS+AQ, 15.2% in
AL, and 9.3% in AS+CD groups respectively) but this was
primarily due to vomiting twice or more within half an hour of
administration of the study drugs. Among the early treatment
failures, 22/23 in AS+AQ, 22/27 in AL, and 13/16 in AS+CD
groups were due to repeated vomiting of study drugs. In the
intention to treat analyses the relative risk (RR) of parasitological
and clinical failure by day 28 corrected for reinfection was lower,
though not statistically significantly, in the AS+AQ group
compared to the AL group (RR 0.75; 95% CI 0.48, 1.14) or to
the AS+CD group (RR 0.81; 95% CI 0.5, 1.27). The relative risk
of parasitological and clinical failure corrected for reinfection was
lower in the AS+AQ group compared to the AL (RR 0.68, 95%
CI 0.47, 0.94) or AS+CD group (RR 0.72, 95% CI 0.49, 1.01).
There was a drop in mean Hb concentration on day 2 post
treatment compared to day 0 in each of the three groups (Table 4).
The mean drop in Hb on day 2 ranged from 0.8 g/dl in the
AS+CD group to 0.4 g/dl in the AL group. By day 7 post
treatment, the mean Hb concentration had recovered to the day 0
levels in the AS+AQ and AL groups and by day 28 the mean Hb
was higher than the day 0 in all three groups. The rate of recovery
of Hb was slightly slower in the AS+CD group compared to the
other two groups.
The reported incidences of solicited adverse events during the 7
days post treatment are shown in Table 5. The incidence of
solicited adverse events was comparable between the three groups.
A history of body pain was more frequent in the AS+AQ group
than the other two groups (Table 5).
G6PD deficient children
There was no statistically significant differences in the
parasitological or clinical failure rates by day 14 or day 28
between the AS+AQ and AL groups (Table 6). The drop in mean
Hb by day 3 post treatment and the recovery in Hb by day 28
were comparable between AS+AQ and AL groups and there was
no apparent difference in the distribution of Hb concentrations
following treatment between the G6PD normal and deficient
children (data not shown).
Discussion
In our study population, the parasitological and clinical failure
at day 28 was lower in the AS+AQ group than in AL group. Our
Table 1. Demographic and haematological characteristics at enrolment in G6PD normal children.
Characteristics AS+AQ [N=178] AL [N=177] AS+CD [N=178] P
n( % ) n( % ) n( % )
Age (months)
6–11 26 (14.6) 25 (14.0) 22 (12.4) 1.0
12–59 119 (66.9) 120 (67.4) 122 (68.5)
60+ 32 (18.0) 33 (18.5) 34 (19.1)
Mean (SD) 37.6 (24.3) 36.8 (26.2) 39.4 (25.0) 0.6
Gender
Male 83 (46.9) 94 (52.8) 92 (51.7) 0.5
Female 94 (52.8) 84 (47.2) 86 (48.3)
Weight (Kg)
,9.9 50 (28.1) 54 (30.3) 46 (25.8) 0.8
10.0–19.9 117 (65.7) 112 (62.9) 118 (66.3)
20.0+ 10 (5.6) 12 (6.7) 14 (7.9)
Mean (SD) 12.6 (4.3) 12.4 (4.5) 12.6 (4.3) 0.9
Temperature (uC)
$37.5 106 (59.6) 107 (60.1) 97 (54.5) 0.5
Mean (SD) 37.9 (1.1) 39.9 (1.1) 37.7 (1.1) 0.3
Parasite Density/mL
,2500 39 (21.9) 31 (17.4) 32 (18.0) 0.2
2500-,10000 42 (23.6) 28 (15.7) 36 (20.2)
$10000 96 (53.9) 119 (66.9) 110 (61.8)
Geometric mean (range) 12507 (1000, 198520) 16521 (1000, 197360) 13820 (1000,199280)
Gametocytaemia 10 (5.6) 11 (6.2) 16 (9.0) 0.4
Haemoglobin (g/dL)
6-,11 163 (91.6) 167 (93.8) 165 (92.7) 0.8
11+ 14 (7.9) 11 (6.2) 13 (7.3)
Mean (SD) 9.1 (1.4) 8.9 (1.3) 8.9 (1.4) 0.3
AS=artesunate; AQ=amodiaquine; AL=artemether-lumefantrine; CD=chlorproguanil-dapsone
doi:10.1371/journal.pone.0002530.t001
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that previously reported from Ghana[8] for AS+AQ (6.6% vs
2.5%) and remarkably higher for AL (13.8% vs 0%). The reason
for the substantially higher parasitological failure at day 28 for AL
compared to the results of a previous study in Ghana[8] and
elsewhere[9] is unclear. Dietary differences between our popula-
tion and the previously studied populations is a possible
explanation for this difference; poor absorption of AL leading to
a higher parasitological failure compared to that reported from
elsewhere. We did not follow the recommended practice of
administering AL with a fatty diet in a clinical trial; instead we
only advised caretakers to give fatty food at the time of drug
administration. This was a pragmatic decision because in routine
health care setting one can only advise a caretaker to administer
AL with a fatty meal. Thus, the observed higher treatment failure
of AL observed in our study compared with others may have been
due to the lack of intake of fat along with AL, as is likely to happen
frequently in routine clinical practice.
Although there was a significant difference in the parasitological
failure rate (both recrudescence and re-infections) at day 28
between AL and AS+AQ, there was no difference in the clinical
failure between the two groups, perhaps because both combina-
tions contain a fast acting artemisinin.
The parasitological or clinical failure of AS+CD by day 14 was
8% and by day 28 (PCR corrected) was 13.8% in our study
population. There are no other published studies of efficacy of
AS+CD with which to compare these results. An earlier
multicountry trial of CD monotherapy showed a parasitological
Figure 2. Proportion of children having treatment failures at different time points during the post treatment period Per protocol
analysis of G6PD normal children.
doi:10.1371/journal.pone.0002530.g002
Table 2. Treatment outcomes (per protocol analysis).
Outcomes AS+AQ [N=151] AL [N=152] AS+CD [N=160] P
*
n( % ) n( % ) n( % )
Early treatment failure 1 (0.7) 5 (3.3) 3 (1.9) 0.257
Late treatment failure 6 (4.0) 7 (4.6) 7 (4.4) 0.960
Parasitological or clinical failure by day 14 8 (5.3) 13 (8.6) 13 (8.1) 0.482
Parasitological or clinical failure by day 28 (PCR uncorrected) 22 (14.6) 42 (27.6) 45 (28.1) 0.005
Parasitological or clinical failure by day 28 (PCR corrected) 10 (6.6) 21 (13.8) 22 (13.8) 0.083
Missing PCR by day 28 (excluded) 3 (2.0) 9 (5.9) 13 (8.1) -
Gametocytaemia by day 7 3 (2.0) 0 (0) 6 (3.8) 0.043
AS=artesunate; AQ=amodiaquine; AL=artemether-lumefantrine; CD=chlorproguanil-dapsone
*exact P values
doi:10.1371/journal.pone.0002530.t002
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suggests that adding AS to CD may have little value in West Africa
given that the PCR corrected failure rate by day 28 has already
reached 13.8%. Surprisingly, the PCR corrected failure rate by
day 28 for AL was also 13.8% and this suggests that introducing
AL as a replacement for AS+AQ needs to considered with caution.
More evidence on the efficacy of AL in Ghana is needed urgently.
In the AL group, all children who had gametocytes on day 0
(n=11) had cleared gametocytes by day 3 post treatment;
gametocytes appeared in the blood of two children between day
14 and 28. In children in the AS+AQ group who had gametocytes
Table 3. Comparison of treatment outcomes between groups (per protocol analysis).
Outcomes AS+AQ vs AL P
* AS+AQ vs AS+CD P
* AS+CD vs AL P
*
RR (95% CI) RR (95% CI) RR (95% CI)
Parasitological or clinical failure by day 14 0.69 (0.28,1.63) 0.4 0.67 (0.27,1.55) 0.4 1.08 (0.49,2.22) 0.8
Parasitological of clinical failure by day 28 (PCR uncorrected) 0.53 (0.32,0.85) 0.007 0.51 (0.30,0.81) 0.004 1.01 (0.68,1.41) 1.0
Parasitological of clinical failure by day 28 (PCR corrected) 0.48 (0.23,0.98) 0.044 0.43 (0.20,0.89) 0.023 1.03 (0.57,1.47) 0.9
AS=artesunate; AQ=amodiaquine; AL=artemether-lumefantrine; CD=chlorproguanil-dapsone
*since there are three comparisons Bonfferroni correction is applied; the P value has to ,0.017 to be statistically significant
doi:10.1371/journal.pone.0002530.t003
Table 4. Haemoglobin concentration during the post treatment period in the study groups.
Post treatment day AS+AQ (n=151) AL (n=152) AS+CD (n=160) P
*
Mean Hb g/dl (SD) Mean Hb g/dl (SD) Mean Hb g/dl (SD)
0 9.0 (1.3) 9.2 (1.4) 8.9 (1.3) 0.2
1 8.5 (1.6) 8.7 (1.6) 8.3 (1.4) 0.08
2 8.3 (1.7) 8.8 (1.7) 8.1 (1.6) 0.002
3 8.8 (1.8) 8.9 (1.6) 8.4 (1.5) 0.045
7 9.0 (1.7) 9.3 (1.6) 8.6 (1.5) 0.001
28 9.9 (1.7) 10.0 (1.6) 9.7 (1.6) 0.3
AS=artesunate; AQ=amodiaquine; AL=artemether-lumefantrine; CD=chlorproguanil-dapsone
SD=standard deviation
*since there are five time points compared against the baseline (day 0), Bonfferroni correction is applied; the P value has to ,0.008 to be statistically significant
doi:10.1371/journal.pone.0002530.t004
Table 5. Distribution of solicited adverse events during the 7-
day post treatment period.
Reported symptoms
AS+AQ
(n=178)
AL
(n=177)
AS+CD
(n=178) P
*
(Adverse events) n (%) n (%) n (%)
Unable to suck/drink 8 (4.5) 5 (2.8) 2 (1.1) 0.11
F e v e r 0( 0 ) 0( 0 ) 0( 0 ) -
Runny nose 29 (16.3) 30 (17.0) 14 (7.9) 0.03
Cough 33 (18.5) 23 (13.0) 21(11.8) 0.30
Difficulty in breathing 3 (1.7) 4 (2.3) 2 (1.1) 0.48
Diarrhoea 13 (7.3) 19(10.7) 11(6.2) 0.44
Vomiting 8(4.5) 6(3.4) 12 (6.7) 0.58
Itching/pruritus 13 (7.3) 10 (5.7) 10 (5.6) 0.93
Loss of appetite 61 (34.3) 44 (24.9) 50 (28.1) 0.29
Nausea 2 (1.1) 0 (0.0) 5 (2.8) 0.17
Abdominal pain 31 (17.4) 19 (10.7) 28 (15.7) 0.34
Body pain 25 (14.0) 10 (5.7) 9 (5.1) 0.01
Difficulty in sleeping 2 (12.4) 23 (13.0) 16 (9.0) 0.75
Joint pain 4 (2.3) 1 (0.6) 0 (0.0) 0.28
Palpitation 3 (1.7) 4 (2.6) 5 (2.8) 0.89
Rash 2 (1.1) 3 (1.7) 2 (1.1) 0.97
Ulcers in mouth/tongue 15 (8.4) 12 (6.8) 10 (5.6) 0.82
Yellow eyes 4 (2.3) 3 (1.7) 4 (2.3) 1.00
AS=artesunate; AQ=amodiaquine; AL=artemether-lumefantrine;
CD=chlorproguanil-dapsone
*exact P values
doi:10.1371/journal.pone.0002530.t005
Table 6. Treatment outcomes in G6PD deficient children (Per
protocol analysis)
Outcomes AS+AQ [N=44] AL [N=42] P
*
n( % ) n( % )
Early treatment failure 1 (2.3) 0 (0.0) 0.3
Late treatment failure 1 (2.3) 2 (4.8) 0.5
Parasitological or clinical failure by
day 14
3 (6.8) 2 (4.8) 0.7
Parasitological or clinical failure by
day 28 (PCR uncorrected)
11 (25.0) 11 (26.2) 0.9
Parasitological or clinical failure by
day 28 (PCR corrected)
6/43 (14.0) 4/42 (9.5) 0.5
Missing PCR by day 28 (excluded) 1 (2.3) 0 0.3
AS=artesunate; AQ=amodiaquine; AL=artemether-lumefantrine;
CD=chlorproguanil-dapsone
*exact P values
doi:10.1371/journal.pone.0002530.t006
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Two more children developed gametocytaemia by day 7 but all
children cleared gametocytes by day 14. In children in the AS+CD
group who had gametocytes on day 0 (n=16) 4 children had
gametocytes on day 3 and one child had gametocytes on day 7
Gametocytes appeared in a further child by day 7 but all children
had cleared gametocytes by day 14; two children had developed
gametocytes between day 14 an 28. It appears that all three ACTs
tested in this study are effective at clearing gametocytes and this
property of ACTs should have an effect on the transmission of
malaria.
A slight reduction in the Hb concentration occured during the
early post treatment period in all three treatment groups. Although
differences were not remarkable, the recovery of Hb was slowest
following treatment with AS+CD. There was no difference in the
risk of haemolysis between the three ACTs in G6PD normal
children. However, we cannot comment about the potential risk of
haemolysis associated with AS+CD in an unselected population
because G6PD deficient children were not included in the AS+CD
arm. Results from recently completed multicentre trials indicate
that coformulated AS+CD can cause serious haemolysis in
children who are G6PD deficient so further development of this
drug combination has been halted.
Our study results supports the current policy of AS+AQ as first
line treatment for uncomplicated malaria in Ghana. However, the
slightly higher incidence of adverse events, particularly vomiting
and body pain, associated with use of AS+AQ is a concern. If these
adverse events are common in adults as well then they might
reduce adherence to a full course of the treatment. There were
some reports of adverse events of AQ in the Ghanaian mass media
and this has lead to the general public being reluctant to accept
AS+AQ combination therapy. Although the overall incidence of
adverse events related to AS+AQ group is reasonable, in order to
achieve a good compliance an appropriate communication
strategy is needed in addition to the introduction of the new fixed
combinations of artesunate plus amodiaquine that are currently
being developed.
We conclude that AS+AQ is an appropriate first line treatment
for uncomplicated malaria in Ghana and possibly in neighbouring
countries in West Africa. However, the deployment of AS+AQ
should be linked to a clear information strategy regarding the
potential mild adverse events for health care providers and the
general public. The efficacy and safety of AL when given in the
context of routine care need to be further studied in Ghana and
elsewhere in West Africa.
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